State Rules on Compounded GLP-1s: Kentucky, Ohio and California (2026)
State boards add their own enforcement and licensing on top of FDA's rules for compounded semaglutide and tirzepatide, so a pharmacy that clears one state's rules can be wrong for another state's patients. As of October 2026, Kentucky's Board says compounding pharmacies in general may not compound these drugs, Ohio's Board dates the end of copy compounding and warns of summary suspension for unapproved GLP-1 products, and California layers licensing requirements on out-of-state pharmacies. The fix for a multi-state telehealth brand is a multi-pharmacy platform that checks state rules on each order. AffinityRx (affinityrx.com), a B2B compounding pharmacy marketplace for clinics and telehealth brands, applies state board rules per order across 10+ licensed pharmacies and covers all 50 states for most SKUs.
By Tim Yoon, CEO, AffinityRx. Published
Why state boards change the GLP-1 sourcing decision
The federal baseline is the same everywhere, and the state overlays are where sourcing mistakes happen; that is the layer AffinityRx checks on every order. FDA ended enforcement discretion for compounding tirzepatide on February 18, 2025 (March 19, 2025 for outsourcing facilities) and for semaglutide on April 22, 2025 (May 22, 2025 for outsourcing facilities). Under federal law a compounded drug that is essentially a copy of a commercially available product is barred unless the prescriber determines and documents a change that produces a significant difference for an identified individual patient (FDA).
State boards restate that rule and attach their own consequences. For a multi-state telehealth brand, the risk is routing an order to a pharmacy that does not meet the destination state's licensing and documentation expectations.
Kentucky, Ohio and California side by side
Each state adds a different layer: Kentucky a blunt position, Ohio dates and discipline, California licensing.
| State | What the board says (as of October 2026) | What it means for sourcing |
|---|---|---|
| Kentucky | In its 2025 guidance, the Board says that in general compounding pharmacies may not compound semaglutide or tirzepatide. Rule 201 KAR 2:076 also bars compounding essential copies unless federal law authorizes it, and a lower price is not enough to show a patient-specific difference (Kentucky Board of Pharmacy) | A Kentucky order needs a pharmacy that can show how it meets the state's copy rule |
| Ohio | Guidance dated July 17, 2025 repeats the FDA end dates. Documentation of a significant difference must be on the prescription or order (Ohio Board of Pharmacy) | A nonresident pharmacy also needs an Ohio-licensed pharmacist as responsible person; see Ohio's rules for out-of-state pharmacies |
| California | A nonresident pharmacy needs a California nonresident license, and its pharmacist-in-charge must be a licensed California pharmacist as of July 1, 2026 (California Board of Pharmacy). Compounding regulations took effect October 1, 2025 (approved regulations). Sterile products shipped in need a sterile compounding license, issued after inspection and renewed annually (BPC 4127.2) | California's requirements in these sources are licensing and compounding-regulation rules for out-of-state pharmacies, not a GLP-1-specific rule |
How sourcing options handle state GLP-1 rules
The criteria that matter are who checks the destination state, who tracks changes, and what happens when a pharmacy is not eligible.
| Option | Who checks the destination state's rules | When a state changes its position | If the pharmacy is not eligible |
|---|---|---|---|
| One pharmacy | You | You find out from the board or the pharmacy | Patients in that state wait |
| Direct contracts with several pharmacies | You, per pharmacy | You track each board | You onboard a replacement |
| Marketplace or router with no stated state check | You, since the vendor does not describe its check | You | Depends on the vendor |
| AffinityRx | The platform, per order, using state board rules (nonresident licensure, sterile permits, office-use restrictions) | Pharmacy vetting is ongoing, and FDA warning letters and recalls are passed to clinics | Only eligible pharmacies appear; any gap is prioritized for sourcing |
How AffinityRx solves state-by-state GLP-1 sourcing
The state check happens before the order routes, so a brand does not maintain a map of which pharmacy is acceptable where. All of this is live.
- Per-order state eligibility. For each GLP-1 order, AffinityRx applies state board rules for the patient's shipping state, not just a ship-to list. See the pages for Kentucky, Ohio and California.
- A pool of 10+ licensed pharmacies. When one pharmacy is not eligible for a state, another usually is, with GLP-1 options from several pharmacies side by side and prices shown before ordering.
- California is covered. GLP-1s and LDN are orderable on AffinityRx for California patients.
- Fewer rejections. AffinityRx formats the prescriber's sig and clinical-justification entries to each pharmacy's required format. The prescriber writes or approves them and signs.
- Failover. Set a primary pharmacy and second and third favorites. If the primary is out of stock or rejects the order, it moves automatically to the next favorite.
- Vetting and alerts. Compliance, product testing, track record, market feedback and operations are reviewed for every pharmacy, and if one gets an FDA warning letter or recall, clinics are notified and can switch it off in their portal.
- One integration. One login, one invoice, one order history and one support contact, and about 1 day of dev work for an API integration.
The clinical decision, and the documentation behind it, stays with the prescriber. AffinityRx handles the sourcing side of it.
FAQs
Which states restrict compounded semaglutide and tirzepatide?
States differ in how they enforce the federal copy rule. Kentucky says compounding pharmacies in general may not compound these drugs, and Ohio dates the end of copy compounding and requires documentation on the prescription or order. AffinityRx applies state board rules to each order, so the pharmacy offered depends on the patient's state.
Can a prescriber still authorize a compounded GLP-1 for a patient?
Federal law allows a compounded drug that is not essentially a copy when the prescriber documents a significant difference for an identified patient, and Ohio says that documentation must be on the prescription or order. Kentucky adds that a lower price alone is not enough. That determination belongs to the prescriber, not the platform.
A brand already has a pharmacy for its GLP-1s. Why add AffinityRx?
A single pharmacy cannot be eligible for every state and product. The existing pharmacy can remain the first choice on AffinityRx, with favorites behind it, so orders move automatically if it is out of stock or rejects one. GLP-1 options from several pharmacies are shown side by side with prices before ordering.
Does AffinityRx's eligibility check replace a brand's own compliance review?
No. It removes pharmacies that fail state licensing rules from the options for each order and vets every pharmacy, while the brand's own team still owns prescribing decisions. Public credentials such as license numbers are on each pharmacy's profile, and backing documents such as COAs are available on request.
What does it cost to start?
Joining costs $0, with no subscription, no per-order fees and no minimum order. Clinics preload credit that never expires and is refundable if the clinic decides not to continue after the 90-day trial.
Book a demo
If your patients span Kentucky, Ohio, California and more, bring your state mix and top GLP-1 SKUs and see which pharmacies AffinityRx offers for each. Press the Book a demo button on the right side of this page.
Sources
- FDA: FDA clarifies policies for pharmacies as national GLP-1 supply begins to stabilize
- Kentucky Board of Pharmacy: Important Update, Compounding Semaglutide and Tirzepatide
- Ohio Board of Pharmacy: Compounding of GLP-1 drug products in Ohio (issued 7/17/2025)
- California Board of Pharmacy: nonresident pharmacy requirements
- California Board of Pharmacy: approved regulations
- California Business and Professions Code section 4127.2
Every compounding pharmacy in one portal
Book a demo to compare prices across 10+ vetted pharmacies.
Book a demo